{"id":66936,"date":"2026-06-01T14:23:01","date_gmt":"2026-06-01T06:23:01","guid":{"rendered":"https:\/\/flcube.com\/?p=66936"},"modified":"2026-06-01T14:23:02","modified_gmt":"2026-06-01T06:23:02","slug":"beijing-wantais-9-valent-hpv-vaccine-achieves-nationwide-distribution-across-13000-vaccination-sites-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66936","title":{"rendered":"Beijing Wantai&#8217;s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/603392:SHA\">SHA: 603392<\/a>)<\/strong> announced the nationwide commercial launch of its <strong>9-valent human papillomavirus (HPV) vaccine<\/strong> in mainland China, with distribution now covering approximately <strong>2,300 disease control centers<\/strong> and <strong>13,000 vaccination sites<\/strong> across the country. The <strong>Escherichia coli-based vaccine<\/strong> represents China&#8217;s first domestically developed 9-valent HPV vaccine and provides comprehensive protection against <strong>seven high-risk HPV types (16\/18\/31\/33\/45\/52\/58)<\/strong> and <strong>two low-risk types (6\/11)<\/strong>, addressing approximately <strong>90% of HPV-related cervical cancer cases<\/strong> and genital warts.<\/p>\n\n\n\n<h2 id=\"h-product-profile-amp-regulatory-status\" class=\"wp-block-heading\">Product Profile &amp; Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>9-valent HPV vaccine (E. coli-based platform)<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Females aged 9\u201345 years<\/td><\/tr><tr><td><strong>Dosing Schedule<\/strong><\/td><td><strong>9\u201317 years<\/strong>: Two-dose regimen<br><strong>18\u201345 years<\/strong>: Three-dose regimen<\/td><\/tr><tr><td><strong>Coverage<\/strong><\/td><td>2,300 disease control centers and 13,000 vaccination sites nationwide<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>Commercially available in mainland China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-vaccine-technology-amp-competitive-advantages\" class=\"wp-block-heading\">Vaccine Technology &amp; Competitive Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Innovation:<\/strong> Utilizes <strong>Escherichia coli-based expression system<\/strong>, distinct from yeast-based platforms used by international competitors<\/li>\n\n\n\n<li><strong>Broad Protection:<\/strong> Covers <strong>9 HPV types<\/strong> responsible for approximately <strong>90% of cervical cancers<\/strong> and <strong>90% of genital warts<\/strong><\/li>\n\n\n\n<li><strong>Domestic Manufacturing:<\/strong> Fully produced in China, ensuring supply chain security and potentially lower costs<\/li>\n\n\n\n<li><strong>Age Flexibility:<\/strong> Approved for the broadest age range among HPV vaccines in China (9\u201345 years)<\/li>\n\n\n\n<li><strong>Dosing Optimization:<\/strong> Reduced two-dose schedule for younger patients enhances compliance and reduces healthcare burden<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-implications\" class=\"wp-block-heading\">Market Context &amp; Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">China&#8217;s HPV vaccine market has experienced explosive growth following increased public awareness and government support for cervical cancer prevention. Prior to Wantai&#8217;s entry, the market was dominated by <strong>Merck&#8217;s Gardasil 9<\/strong> and <strong>GSK&#8217;s Cervarix<\/strong>, both imported products facing supply constraints and premium pricing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key market dynamics:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Approximately <strong>150\u2013200 million females<\/strong> aged 9\u201345 in China<\/li>\n\n\n\n<li><strong>Government Support:<\/strong> HPV vaccination included in national cancer prevention initiatives and local government procurement programs<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Domestic production expected to enable <strong>30\u201350% lower pricing<\/strong> compared to imported alternatives<\/li>\n\n\n\n<li><strong>Supply Security:<\/strong> Annual production capacity sufficient to vaccinate <strong>10\u201315 million individuals<\/strong>, addressing historical supply shortages<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This nationwide launch marks a significant milestone in China&#8217;s fight against cervical cancer,&#8221; said Dr. Zhang Xiaoming, Chief Executive Officer of Beijing Wantai. &#8220;By providing affordable, domestically produced 9-valent HPV vaccine coverage across all provinces, we are making comprehensive HPV protection accessible to millions of Chinese women and girls who previously faced barriers due to cost or availability.&#8221;<\/p>\n\n\n\n<h2 id=\"h-public-health-impact\" class=\"wp-block-heading\">Public Health Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The widespread availability of Wantai&#8217;s 9-valent HPV vaccine aligns with China&#8217;s commitment to the <strong>World Health Organization&#8217;s global strategy to eliminate cervical cancer<\/strong>, which calls for <strong>90% of girls to be fully vaccinated by age 15<\/strong> by 2030. The vaccine&#8217;s inclusion in routine immunization programs at disease control centers ensures equitable access across urban and rural populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts estimate the Chinese HPV vaccine market will reach <strong>\u00a515\u201320 billion ($2.1\u20132.8 billion) annually<\/strong> by 2028, with domestic manufacturers like Wantai capturing an increasing share of this rapidly expanding market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market penetration, public health impact, and commercial performance of Wantai&#8217;s 9-valent HPV vaccine. Actual results may vary based on vaccination rates, competitive dynamics, and evolving government policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/603392_20260530_9ZF4.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603392_20260530_9ZF4.\"><\/object><a id=\"wp-block-file--media-1ee4ac39-3e85-4364-9184-373fc6e0dac4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/603392_20260530_9ZF4.pdf\">603392_20260530_9ZF4<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/603392_20260530_9ZF4.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1ee4ac39-3e85-4364-9184-373fc6e0dac4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1011,12,202],"class_list":["post-66936","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-sha-603392","tag-vaccine","tag-wantai-biological-pharmacy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Beijing Wantai&#039;s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of its 9-valent human papillomavirus (HPV) vaccine in mainland China, with distribution now covering approximately 2,300 disease control centers and 13,000 vaccination sites across the country. The Escherichia coli-based vaccine represents China&#039;s first domestically developed 9-valent HPV vaccine and provides comprehensive protection against seven high-risk HPV types (16\/18\/31\/33\/45\/52\/58) and two low-risk types (6\/11), addressing approximately 90% of HPV-related cervical cancer cases and genital warts.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66936\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beijing Wantai&#039;s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China\" \/>\n<meta property=\"og:description\" content=\"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of its 9-valent human papillomavirus (HPV) vaccine in mainland China, with distribution now covering approximately 2,300 disease control centers and 13,000 vaccination sites across the country. The Escherichia coli-based vaccine represents China&#039;s first domestically developed 9-valent HPV vaccine and provides comprehensive protection against seven high-risk HPV types (16\/18\/31\/33\/45\/52\/58) and two low-risk types (6\/11), addressing approximately 90% of HPV-related cervical cancer cases and genital warts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66936\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T06:23:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T06:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66936#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66936\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beijing Wantai&#8217;s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China\",\"datePublished\":\"2026-06-01T06:23:01+00:00\",\"dateModified\":\"2026-06-01T06:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66936\"},\"wordCount\":510,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHA: 603392\",\"Vaccine\",\"Wantai Biological Pharmacy\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66936#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66936\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66936\",\"name\":\"Beijing Wantai's 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T06:23:01+00:00\",\"dateModified\":\"2026-06-01T06:23:02+00:00\",\"description\":\"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of its 9-valent human papillomavirus (HPV) vaccine in mainland China, with distribution now covering approximately 2,300 disease control centers and 13,000 vaccination sites across the country. The Escherichia coli-based vaccine represents China's first domestically developed 9-valent HPV vaccine and provides comprehensive protection against seven high-risk HPV types (16\\\/18\\\/31\\\/33\\\/45\\\/52\\\/58) and two low-risk types (6\\\/11), addressing approximately 90% of HPV-related cervical cancer cases and genital warts.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66936#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66936\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66936#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beijing Wantai&#8217;s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beijing Wantai's 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of its 9-valent human papillomavirus (HPV) vaccine in mainland China, with distribution now covering approximately 2,300 disease control centers and 13,000 vaccination sites across the country. The Escherichia coli-based vaccine represents China's first domestically developed 9-valent HPV vaccine and provides comprehensive protection against seven high-risk HPV types (16\/18\/31\/33\/45\/52\/58) and two low-risk types (6\/11), addressing approximately 90% of HPV-related cervical cancer cases and genital warts.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66936","og_locale":"en_US","og_type":"article","og_title":"Beijing Wantai's 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China","og_description":"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of its 9-valent human papillomavirus (HPV) vaccine in mainland China, with distribution now covering approximately 2,300 disease control centers and 13,000 vaccination sites across the country. The Escherichia coli-based vaccine represents China's first domestically developed 9-valent HPV vaccine and provides comprehensive protection against seven high-risk HPV types (16\/18\/31\/33\/45\/52\/58) and two low-risk types (6\/11), addressing approximately 90% of HPV-related cervical cancer cases and genital warts.","og_url":"https:\/\/flcube.com\/?p=66936","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T06:23:01+00:00","article_modified_time":"2026-06-01T06:23:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66936#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66936"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beijing Wantai&#8217;s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China","datePublished":"2026-06-01T06:23:01+00:00","dateModified":"2026-06-01T06:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66936"},"wordCount":510,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHA: 603392","Vaccine","Wantai Biological Pharmacy"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66936#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66936","url":"https:\/\/flcube.com\/?p=66936","name":"Beijing Wantai's 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T06:23:01+00:00","dateModified":"2026-06-01T06:23:02+00:00","description":"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of its 9-valent human papillomavirus (HPV) vaccine in mainland China, with distribution now covering approximately 2,300 disease control centers and 13,000 vaccination sites across the country. The Escherichia coli-based vaccine represents China's first domestically developed 9-valent HPV vaccine and provides comprehensive protection against seven high-risk HPV types (16\/18\/31\/33\/45\/52\/58) and two low-risk types (6\/11), addressing approximately 90% of HPV-related cervical cancer cases and genital warts.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66936#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66936"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66936#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beijing Wantai&#8217;s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66936"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66936\/revisions"}],"predecessor-version":[{"id":66938,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66936\/revisions\/66938"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}